Loading
Prostate Cancer Diagnosis and Treatment / Advanced Radiotherapy Techniques · Review
Translational Oncology · August 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This systematic review identified 107 clinical prediction models for adverse events after prostate cancer radiotherapy across 35 studies published 2004–2024, but found only 2 models (AUC 0.59 and 0.80) met low-risk-of-bias criteria. The evidence base reveals that most existing models suffer from methodological limitations, miscalibration, and insufficient external validation, limiting their clinical readiness.
Systematic review with structured quality appraisal using validated tool (SF-PROBAST). Studies developing or validating clinical prediction models for adverse events (urinary, bowel, sexual, other) following prostate cancer curative radiotherapy.. Intervention: Clinical prediction models for adverse events after prostate cancer radiotherapy (various designs and populations across 107 models). Compared with: Comparison of model methodological quality and performance across studies using standardized SF-PROBAST appraisal criteria. Not specified.
Of 3606 records screened, 136 CPM studies identified and 35 included, yielding 107 CPMs total Most models (n=87) developed in external beam radiation therapy populations Only 2 models classified as low risk of bias (AUC=0.59 and 0.80)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that few existing prediction models for prostate cancer radiotherapy toxicity meet methodological standards for clinical deployment. Current evidence supports prioritizing validation and refinement of established models rather than adopting new unvalidated tools for individual patient counseling.
Systematic review of prediction model quality showing most existing models have methodological limitations and lack external validation; identifies a gap rather than establishing a ready-to-use clinical tool.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that few existing prediction models for prostate cancer radiotherapy toxicity meet methodological standards for clinical deployment. Current evidence supports prioritizing validation and refinement of established models rather than adopting new unvalidated tools for individual patient counseling.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: Predicting risks of urinary, bowel, sexual, and other adverse effects following prostate cancer curative radiotherapy (PCa-RT) is essential for treatment personalization and patient counseling. Several clinical prediction models (CPMs) have been published; however, their methodological quality remains unclear. METHODS: We systematically reviewed studies developing or validating CPMs for adverse events after PCa-RT. Embase and Medline were searched for CPM studies for patient- or clinician-reported outcomes (PROs/ClinROs), published between January 1, 2004, and August 6, 2024. To focus the appraisal on methodologically more robust models, models were pre-selected based on events per variable ≥10 or the reporting of optimism-corrected performance metrics or effect estimates. We appraised models based on performance and ROB, using a six-item short form of the Prediction model Risk Of Bias ASsessment Tool (SF-PROBAST). RESULTS: Of 3606 records screened, 136 CPM studies were identified, and 35 were included, yielding 107 CPMs. Most models (n = 87) were developed in external beam radiation therapy populations. 22 models were externally validated. Only two models (AUC= 0.59 and 0.80) - developed in two different studies - were classified as low risk of bias (fulfilled all the SF-PROBAST criteria). 32 models, from 13 studies, met at least four SF-PROBAST criteria and showed at least moderate discrimination (AUC ≥ 0.70) at internal (n = 25) and/or external (n = 11) validation. CONCLUSION: Ready-to-use CPMs in PCa-RT remain scarce due to methodological limitations, miscalibration, and lack of external validation. Future efforts should prioritize validation and refinement of existing models rather than development of new ones.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.